These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 33430823)

  • 1. Toward patient-centered tuberculosis preventive treatment: preferences for regimens and formulations in Lima, Peru.
    Yuen CM; Millones AK; Galea JT; Puma D; Jimenez J; Lecca L; Becerra MC; Keshavjee S
    BMC Public Health; 2021 Jan; 21(1):121. PubMed ID: 33430823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost of Delivering 12-Dose Isoniazid and Rifapentine Versus 6 Months of Isoniazid for Tuberculosis Infection in a High-Burden Setting.
    Yuen CM; Majidulla A; Jaswal M; Safdar N; Malik AA; Khan AJ; Becerra MC; Keshavjee S; Lu C; Hussain H
    Clin Infect Dis; 2021 Sep; 73(5):e1135-e1141. PubMed ID: 33289039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.
    Sharma SK; Sharma A; Kadhiravan T; Tharyan P
    Evid Based Child Health; 2014 Mar; 9(1):169-294. PubMed ID: 25404581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of latent tuberculosis infection.
    Parekh MJ; Schluger NW
    Ther Adv Respir Dis; 2013 Dec; 7(6):351-6. PubMed ID: 24056289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contact evaluation and isoniazid preventive therapy among close and household contacts of tuberculosis patients in Lima, Peru: an analysis of routine data.
    Otero L; Battaglioli T; Ríos J; De la Torre Z; Trocones N; Ordoñez C; Seas C; Van der Stuyft P
    Trop Med Int Health; 2020 Mar; 25(3):346-356. PubMed ID: 31758837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Scale-Up of Rifapentine and Isoniazid for Tuberculosis Prevention Among Household Contacts in 2 Urban Centers: An Effectiveness Assessment.
    Hussain H; Jaswal M; Farooq S; Safdar N; Madhani F; Noorani S; Shahbaz SS; Salahuddin N; Amanullah F; Khowaja S; Manzar S; Shah JA; Islam Z; Dahri AA; Shahzad M; Keshavjee S; Becerra MC; Khan AJ; Malik AA
    Clin Infect Dis; 2023 Aug; 77(4):638-644. PubMed ID: 37083926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rifampicin and isoniazid prophylactic chemotherapy for tuberculosis.
    Ormerod LP
    Arch Dis Child; 1998 Feb; 78(2):169-71. PubMed ID: 9579163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of 3 months of weekly rifapentine and isoniazid compared with other standard treatment regimens for latent tuberculosis infection: a decision analysis study.
    Doan TN; Fox GJ; Meehan MT; Scott N; Ragonnet R; Viney K; Trauer JM; McBryde ES
    J Antimicrob Chemother; 2019 Jan; 74(1):218-227. PubMed ID: 30295760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and feasibility of 1 month of daily rifapentine plus isoniazid to prevent tuberculosis in children and adolescents: a prospective cohort study.
    Malik AA; Farooq S; Jaswal M; Khan H; Nasir K; Fareed U; Shahbaz S; Amanullah F; Safdar N; Khan AJ; Keshavjee S; Becerra MC; Hussain H
    Lancet Child Adolesc Health; 2021 May; 5(5):350-356. PubMed ID: 33770510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paediatric tuberculosis preventive treatment preferences among HIV-positive children, caregivers and healthcare providers in Eswatini: a discrete choice experiment.
    Hirsch-Moverman Y; Strauss M; George G; Mutiti A; Mafukidze A; Shongwe S; Dube GS; El Sadr WM; Mantell JE; Howard AA
    BMJ Open; 2021 Oct; 11(10):e048443. PubMed ID: 34686549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts.
    Schechter M; Zajdenverg R; Falco G; Barnes GL; Faulhaber JC; Coberly JS; Moore RD; Chaisson RE
    Am J Respir Crit Care Med; 2006 Apr; 173(8):922-6. PubMed ID: 16474028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of rifapentine for preventive therapy in the Cornell mouse model of latent tuberculosis.
    Miyazaki E; Chaisson RE; Bishai WR
    Antimicrob Agents Chemother; 1999 Sep; 43(9):2126-30. PubMed ID: 10471552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlates of isoniazid preventive therapy failure in child household contacts with infectious tuberculosis in high burden settings in Nairobi, Kenya - a cohort study.
    Okwara FN; Oyore JP; Were FN; Gwer S
    BMC Infect Dis; 2017 Sep; 17(1):623. PubMed ID: 28915796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of Preventive Therapy for Tuberculosis With Isoniazid and Rifapentine Versus Isoniazid Alone in High-Burden Settings.
    Johnson KT; Churchyard GJ; Sohn H; Dowdy DW
    Clin Infect Dis; 2018 Sep; 67(7):1072-1078. PubMed ID: 29617965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial.
    Hosseinipour MC; Bisson GP; Miyahara S; Sun X; Moses A; Riviere C; Kirui FK; Badal-Faesen S; Lagat D; Nyirenda M; Naidoo K; Hakim J; Mugyenyi P; Henostroza G; Leger PD; Lama JR; Mohapi L; Alave J; Mave V; Veloso VG; Pillay S; Kumarasamy N; Bao J; Hogg E; Jones L; Zolopa A; Kumwenda J; Gupta A;
    Lancet; 2016 Mar; 387(10024):1198-209. PubMed ID: 27025337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful implementation of isoniazid preventive therapy at a pediatric HIV clinic in Tanzania.
    Hunter OF; Kyesi F; Ahluwalia AK; Daffé ZN; Munseri P; von Reyn CF; Adams LV
    BMC Infect Dis; 2020 Oct; 20(1):738. PubMed ID: 33028260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. US Guidelines Fall Short on Short-Course Tuberculosis-Preventive Therapy.
    Krishnan S; Chaisson RE
    Clin Infect Dis; 2024 Mar; 78(3):514-517. PubMed ID: 37879092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid.
    Villarino ME; Scott NA; Weis SE; Weiner M; Conde MB; Jones B; Nachman S; Oliveira R; Moro RN; Shang N; Goldberg SV; Sterling TR; ;
    JAMA Pediatr; 2015 Mar; 169(3):247-55. PubMed ID: 25580725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Barriers to the treatment of childhood tuberculous infection and tuberculosis disease: a qualitative study.
    Chiang SS; Roche S; Contreras C; Del Castillo H; Canales P; Jimenez J; Tintaya K; Becerra MC; Lecca L
    Int J Tuberc Lung Dis; 2017 Feb; 21(2):154-160. PubMed ID: 28234078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.